Supplementary Table S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

Elena Shagisultanova; William J. Gradishar; Ursa Brown-Glaberman; Pavani Chalasani; Andrew Brenner; Alison Stopeck; Hannah Parris; Dexiang Gao; Tessa McSpadden; José Mayordomo; Jennifer R. Diamond; Peter Kabos; Virginia F. Borges

doi:10.1158/1078-0432.30833939

Abstract

<p>Serious adverse events</p>

Related Publications

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn , Baek‐Yeol Ryoo , Philippe Merle +17 more

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). K...

2019 Journal of Clinical Oncology 1737 citations

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng , Yoon‐Koo Kang , Zhendong Chen +18 more

Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and safe...

2008 The Lancet Oncology 5750 citations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Melody Cobleigh , Charles L. Vogel , Debu Tripathy +8 more

PURPOSE: Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recom...

1999 Journal of Clinical Oncology 2778 citations

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patien...

2019 The Lancet Oncology 1593 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Supplementary Table S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Elena Shagisultanova, 
                                
                                    William J. Gradishar, 
                                
                                    Ursa Brown-Glaberman
                                
                                et al.
                            
                            (2025). 
                            Supplementary Table S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer. 
                            
                            .
                            https://doi.org/10.1158/1078-0432.30833939

Identifiers

DOI: 10.1158/1078-0432.30833939